# Effects and Feasibility of Photobiomodulation at 830nm Nanometers in the Treatment of Diabetic Ulcers

Study · id `cardio:ct-nct07043868` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07043868](<https://clinicaltrials.gov/study/NCT07043868>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07043868

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 136 participants.

## Technical summary

Registry record NCT07043868. Randomized; triple masking; primary purpose health services research. Start 2026-01-10 (anticipated); primary completion 2027-01-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose health services research
- Phase: Not applicable
- Enrolled: 136 participants (planned count; ClinicalTrials.gov record NCT07043868, source copy `cardio:ctgov-nct07043868-2025-07-10`, retrieved 2026-10-26)
- Planned start: 2026-01-10 (anticipated) (ClinicalTrials.gov record NCT07043868, source copy `cardio:ctgov-nct07043868-2025-07-10`, retrieved 2026-10-26)
- Primary completion: 2027-01-10 (anticipated) (ClinicalTrials.gov record NCT07043868, source copy `cardio:ctgov-nct07043868-2025-07-10`, retrieved 2026-10-26)
- Completion: 2028-01-10 (anticipated) (ClinicalTrials.gov record NCT07043868, source copy `cardio:ctgov-nct07043868-2025-07-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07043868-2025-07-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects and Feasibility of Photobiomodulation at 830nm Nanometers in the Treatment of Diabetic Ulcers
- Condition: Diabete Type 2
- Condition: Diabetic Foot Ulcer
- Condition: Photobiomodulation
- Condition: Low Level Laser Therapy
- Intervention (Device): Low Level Laser Therapy
- Lead sponsor: Federal University of Piaui
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 1451814ad9760ed63ad7eee39e51858f7e81cc5c687c32ac461a03c285f14642
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
